Search Results
PCSK9 Inhibitors: Cost Concerns and Access
High Cost Impacts PCSK9 Inhibitor Access
How Can Access to PCSK9 Inhibitors be Improved?
Patient Access to PCSK9 Inhibitors
PCSK9 Inhibitors Show Benefits with Challenges to Overcome
Kevin Maki, PhD: Balancing Cost and Benefit With PCSK9 Inhibitors
Access Considerations for PCSK9 Inhibitors
LDL-Lowering PCSK9 Inhibitors: Why We Aren’t Using Them “All the Time"
Weighing the Risks and Concerns of PCSK9 Inhibitors with Benefits to Patients
PCSK9 Inhibitors: Access Barriers Affect Real People
PCSK9 drug costs
Cost-effectiveness of PCSK9 Inhibitors for Heterozygous FH or ASCVD
